Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant.

This study evaluated the impact of genotype and other patient characteristics on sublingual (SL) tacrolimus exposure and compared the relationship with oral administration. Tacrolimus concentrations were retrospectively collected for adult lung transplant recipients, who were genotyped for , , , and . Regression analyses were performed to determine covariates that impacted the SL and oral tacrolimus concentration/dose ratios. An interaction of genotype and CYP3A inhibitor increased the SL concentration/dose, while cystic fibrosis decreased the SL concentration/dose. The oral concentration/dose was independently associated with these covariates and was increased by serum creatinine and number of tacrolimus doses. This study suggests personalized dosing strategies for tacrolimus likely need to consider characteristics beyond genotype.